Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Increases Target Amount on Proposed IPO to $74.3M

NEW YORK (GenomeWeb) – AltheaDx has raised the target amount on its proposed initial public offering to about $74.3 million from $69 million, it disclosed in an amended prospectus filed with the US Securities and Exchange Commission last week. 

The company said that it expects to fetch between $12 and $14 per share from its IPO and plans to offer a little more than 4.6 million shares of its common stock. At the midpoint price of $13 per share, net proceeds from the offering are anticipated to be $52.2 million, or $60.6 million if the underwriters exercise their overallotment option in full, AltheaDx said. 

AltheaDx plans to list on the Nasdaq Global Market under ticker symbol "IDGX." Citigroup and Jefferies are the joint book-running managers on the proposed offering, and William Blair and Cantor Fitzgerald are the co-managers. 

AltheaDx said in its amended prospectus that it expects to use about $15 million of net proceeds for R&D, including clinical studies to demonstrate the utility of its products, the expansion of its IDgenetix tests, and to support efforts to secure reimbursement. 

The IDgenetix portfolio of tests enables clinicians to tailor treatments for cardiovascular disease, neuropsychiatric disorders, and pain, AltheaDx said. 

Another $15 million will be used to expand sales and marketing operations related to the IDgenetix tests, while $10 million will go toward expanding AltheaDx's facilities and laboratory operations. Remaining proceeds will be used for working capital and general corporate purposes, as well as for licensing deals, acquisitions, and investments in complementary businesses, technologies, products, and assets, the company said. 

The molecular diagnostics company filed for an IPO a month ago.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.